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no relationsh“I’m goin’ home
And when I wanna go home
I’m goin’ mobile
Well, I’m gonna ﬁnd a home
And we’ll see how it feels
Goin’ mobile
Keep me movin’”dPete Townshend, The Who, 1971 (1)
Although mortality following myocardial infarction (MI)
has decreased signiﬁcantly over the past decades (2), the
frequency of left ventricular systolic dysfunction or heart
failure remains high, ranging from 10% to 20% (3–5).
Improvements in outcome following MI have resulted
from addressing speciﬁc aspects of the pathophysiology
with thrombolytic drugs and percutaneous revascularization,
aspirin, statin drugs, angiotensin-converting enzyme in-
hibitors, beta-blockers, and aldosterone antagonists.See page 2862In the past 15 years, however, attention has increasingly
focused on the prospect of attenuating, if not reversing, the
degree of damage to the myocardium by leveraging naturally
existing repair mechanisms.
In 1997, Asahara et al. (6) ﬁrst described the existence of
endothelial progenitor cells (EPCs). The concept that adults
had vasculogenic progenitors that could be used therapeu-
tically (7) quickly triggered the evaluation of cell-based
therapies to improve long-term outcomes post-MI (8,9).
The concept that EPCs from the bone marrow were part
of the natural response toMI was ﬁrst noted by Shintani et al.
(10) in 2001. Subsequently, Werner et al. (11) showed thatublished in the Journal of the American College of Cardiology reﬂect the
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cardiovascular mortality rates of 1.8% versus rates of 8.3%
in the worst mobilizers. The variability in outcomes following
MI, despite an apparently similar initial clinical course, is well
known, and now data are emerging that part of that vari-
ability was due to the variable ability to trigger native tissue
repair mechanisms; however, the mechanisms responsible for
this variability are not yet completely understood.
In this issue of the Journal, Gong et al. (12) document a
novel function of plasminogen (Plg) in stem cell–mediated
cardiac repair, speciﬁcally, the requirement for Plg for stem
cell mobilization and for C-X-C chemokine receptor type
4 (CXCR4)–mediated homing to ischemic myocardium.
Leveraging their previous work that documented the regula-
tion of stromal derived factor-1 (SDF-1)/CXCR4-mediated
stem cell mobilization (13), they extend the ﬁndings to show
that stem cell–mediated repair can be rescued despite Plg
deﬁciency by forced expression of CXCR4.
Impaired ﬁbrinolysis has been known to be associated with
the risk of coronary disease for decades (14,15), and in the past
decade or so, its importance in the maintenance of bone
marrow stem cell niches andmobilization has also been shown
(16). More recently, the link between the ﬁbrinolytic system
andbonemarrow–derived stemcell–mediated tissue repair has
been explored (17), and deﬁciencies in this system have been
discovered in patient populations, such as diabetic patients
(18), who have poor outcomes following MI. Furthermore, 2
recent studies have reported that pharmacological inhibition
of plasminogen activator inhibitor-1 promotes cell-mediated
angiogenesis (19) and hematopoietic regeneration (20).
Accordingly, a more complete understanding of the
mechanisms that mediate the natural protection and repair
of the myocardium following MI are an increasingly im-
portant part of the quest to mitigate the long-term sequelae
following an MI.
There are 2 basic elements of the stem cell–mediated
repair of the myocardium: mobilization and homing/reten-
tion in the target tissue.
Mobilization of stem cells from the bone marrow is known
to result from an exquisitely regulated cascade of events that
involves the matrix metalloproteinase-9–mediated release of
soluble Kit ligand. Stem cell mobilization has been shown to
be triggered by the sympathetic nervous system (21), which
likely explains the increase in EPCs seen followingMI and by
milder forms of stimulation such as exercise (22). Pharma-
cologic approaches to increased mobilization of EPCs have
proven effective in pre-clinical models, including the use of
granulocyte colony-stimulating factor or selective CXCR4
antagonists (23,24). In view of its beneﬁt in animal models,
the failure of granulocyte colony stimulating factor to improve
outcomes following MI was disappointing; however, this
could relate to the requirement for speciﬁc bone marrow cell
subtypes to mediate repair versus inﬂammation (25–27).
Homing of EPCs to ischemic tissue has been explored in
pre-clinical and early-phase clinical trials. Askari et al. (28)
showed that the overexpression of SDF-1 resulted in
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2874increased EPC homing and vascularization in models of
acute and chronic myocardial injury with resultant im-
provements in ventricular function, and Yamaguchi et al.
(29) showed enhanced function of locally transplanted EPCs
in a model of limb ischemia. More recently, a pilot study
showed evidence that a gene therapy approach to over-
expression of SDF-1 in patients with chronic heart failure
may exert beneﬁcial effects on clinical symptoms and
remodeling (30). Because SDF-1 is the ligand for CXCR4,
this is also consistent with the work of Gong et al. (12).
The potential beneﬁt of increasing the effects of bone
marrow–derived progenitor cells for repair of MI has now
been illustrated by a large number of clinical studies (31). At
the same time, it is clear that increased beneﬁt will likely
result from selective mobilization and homing of cell types
that are responsible for repair. Accordingly, to maximally
leverage these “pre-installed” mechanisms for self-repair,
ongoing pre-clinical studies, informed by ongoing clinical
trials, will be needed to reﬁne the treatment of MI with the
goal of making the notions of “permanent” myocardial injury
a thing of the past.
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